Currently submitted to: JMIR Bioinformatics and Biotechnology
Date Submitted: Apr 3, 2019
Open Peer Review Period: Apr 8, 2019 - Jun 3, 2019
(currently open for review)
Click by Click Molecular Docking for non-bioinformaticians using Chimera 1.12
In the field of drug discovery, many methods of molecular modeling have been employed to study the complex biological and chemical systems. Experimental strategies are integrated with computational approaches in the identification, characterization and development of novel drugs and compounds. Molecular Docking is the approach in the modern drug design that explores the confirmation of ligand within the binding site of the macromolecule. To date many software’s and tools for Docking have been employed. AutoDock Vina (in UCSF Chimera) is one of the computationally fast and accurate software employed in Docking. In this paper, a sequential demonstration of molecular Docking of ligand Fisetin with the target protein Akt has been provided, using AutoDock Vina in UCSF Chimera 1.12. The first step involves the target protein ID retrieval from PDB, the second step is to visualize the structure of protein in UCSF Chimera, the third step is to prepare the target protein for Docking, the fourth step is preparing the ligand for docking, the fifth step is the Docking of ligand and the target protein as Mol.2 files in Chimera using AutoDock Vina and the final step is the interpretation and analysis of Docking results. By following the guidelines and the steps used in this paper, the researchers who have no previous background in bioinformatics research can perform computational Docking in a more user-friendly and easy manner.
Note: Per the author's request, please log in to view the PDF
© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.